White House Withdraws Heidi Overton’s FDA Nomination a Day Before Senate Committee Vote

The White House dropped Dr. Heidi Overton's nomination to lead the FDA a day before a Senate committee vote. Sen. Bill Cassidy faulted the decision.

Updated

Share this article

Featured photo: President Donald Trump signs an executive order on childhood vaccines in the Oval Office on Aug. 10, 2026, with Dr. Heidi Overton among those present (file photo). Photo: Molly Riley, The White House, Wikimedia Commons, public domain.
1 day
before the Senate health committee was due to vote
May
when the FDA last had a Senate-confirmed commissioner
20%
approximate share of U.S. consumer spending on FDA-regulated products
March
when the FDA is set to finish its mifepristone safety review

The White House dropped the nomination of Dr. Heidi Overton to lead the Food and Drug Administration on Tuesday, Nov. 17.[1][2] The Senate Health, Education, Labor and Pensions Committee had been scheduled to vote on the nomination Wednesday.[1] A White House official confirmed the decision to NBC News.[2]

Related: Cassidy Calls RFK Jr.’s Tenure a ‘Failure’ and Says Trump Should Change Health Secretaries.

Advertisement

Why the nomination stalled

Overton had struggled to win enough support among Senate Republicans.[1] Some lawmakers and administration allies were skeptical of her testimony on the abortion drug mifepristone.[1] Others questioned her role in carrying out President Donald Trump’s vaping policies.[1]

The committee math left almost no margin, though two outlets described it differently. NBC News reported that Overton needed 11 votes on a 21-member committee and could not lose a single Republican if all Democrats opposed her.[2] The Guardian reported that she needed all 12 Republicans on a committee where Democrats hold 11 seats.[3]

Sen. Josh Hawley, R-Mo., was among the skeptics.[4] Sens. Susan Collins of Maine and Lisa Murkowski of Alaska had not said how they would vote.[4] No Democrat on the committee was expected to back her.[4]

Sen. Bill Cassidy, R-La., the committee chairman, had questioned whether Overton had enough experience to lead the agency.[2] He had also called her support for Trump’s plan to break up combination vaccines “almost disqualifying,” The Guardian reported.[3]

Cassidy faults the White House

Cassidy criticized the withdrawal on Tuesday night. “Tonight, the White House abandoned a viable confirmation path for Dr. Overton,” Cassidy wrote on X.[2]

Cassidy said senators who oppose abortion had sought final assurances about the administration’s “commitment to life issues.”[2] “The Administration withdrew Dr. Overton rather than make such commitments,” he wrote.[2]

“I believe she would have had the votes to pass out of committee and pass the full Senate,” Cassidy said in a statement.[1] Two sources told CBS News that efforts to round up Republican votes were still under way when the White House shared its decision.[1]

An abortion rights group welcomed the move. Mini Timmaraju, president of Reproductive Freedom for All, said Overton “posed a serious threat to the future of medication abortion access.”[3]

Who Overton is

Overton is a physician and a White House domestic policy staffer.[1] She previously worked as chief policy officer at the America First Policy Institute, a conservative think tank.[2] Trump nominated her in August.[3] Her confirmation hearing took place in September.[2]

Advertisement

Overton has called for strict restrictions on medication abortion.[2] At her hearing, Murkowski criticized her for not taking a clear position on access to mifepristone.[2] The anti-abortion group Susan B. Anthony had urged the Senate to delay her confirmation.[4]

What comes next for the FDA

The FDA has not had a Senate-confirmed leader since Dr. Marty Makary left in May.[1] Acting Commissioner Kyle Diamantas runs the agency.[1] The FDA regulates products that account for about 20% of U.S. consumer spending.[1]

The White House had begun talking to other candidates before the withdrawal, a source told CBS News.[1] Some could serve in an acting capacity, which does not require Senate confirmation.[1] Two sources told CBS News that Sen. Roger Marshall of Kansas, a doctor who lost his reelection bid this month, is seeking the post.[1] That account is unconfirmed.

Democrats take control of the Senate in early January.[2] “With the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats,” Cassidy wrote.[2] The FDA is set to finish its safety review of mifepristone in March.[2]

Nominations and the Senate calendar are followed on the Congress tracker. More coverage is on the politics and government hub.

Sources

  1. CBS News: White House drops its nomination for FDA commissioner
  2. NBC News: White House drops Heidi Overton’s FDA nomination after Republicans raise concerns
  3. The Guardian: White House withdraws nomination of Heidi Overton to lead FDA
  4. CBS News: Trump FDA nominee Heidi Overton struggling to win enough GOP support to be confirmed

About the reporter: Marcus Hale is an AI reporter covering politics for The Boston Report. This article was produced with AI under our editorial policy. Read our AI and media disclosure.

Read next in Politics

Get The Boston Report Briefing

Our free weekly email with the most important stories from Boston and the world. Unsubscribe anytime.

Free. We never sell your address. Privacy policy

Get The Boston Report Briefing
Our free weekly email with the most important stories from Boston and the world. Unsubscribe anytime.
Sign up